Big Development in Cardiac Arrhythmia Monitoring Devices: Study Shows Benefits of Monitoring Heart Arrhythmia Remotely

  • Analysis
  • 23-December-2021

Several medications, including some for arrhythmias and cancer, necessitate continual monitoring of the patient's heart rhythms. Patients are sometimes forced to stay in the hospital for the first three days to receive two ECGs (Electrocardiography). Each day, the process goes on before the drug is judged safe to use at home. Remote monitoring might save healthcare systems a lot of money and provide patients more time because they wouldn't need to stay in the hospital for three days and miss work merely to have six ECGs.
Researchers have demonstrated through a study that participants can be monitored for potential arrhythmic effects of medicines safely and successfully at home. The findings could be highly beneficial to Cardiac Arrhythmia Monitoring Devices because they highlight the advantages of remote monitoring of the ailment, which would reduce the stress on healthcare systems while also saving patients money on treatment costs.

During COVID-19's first wave, the fully remote study was undertaken in the early spring of 2020.
Researchers sought to see if the cheap medications, hydroxychloroquine and azithromycin, may help patients—particularly those who had tested positive for SARS-CoV-2 and were self-treating at home recover faster. However, the researchers were concerned that the medications could cause a cardiac rhythm abnormality known as a prolonged QT interval. Long QT can lead to cardiac arrest if left untreated.
Before the experiment was halted due to a lack of therapeutic benefit, 218 participants were enrolled. The team started studying medication and sent ECG data into three randomized arms. All readings were transmitted within an hour. Participants whose QT interval was significantly higher than baseline were asked to get another ECG right away, and if that test confirmed the finding, the drug was stopped. Twenty-eight participants had prolonged QT, and two of them had to stop taking their medications as a result. There were no fatalities reported.
More crucially, 85 percent of participants followed the trial's procedure of submitting one ECG every day for the first 14 days, indicating that remote arrhythmia monitoring is possible.
The research undertaken to test two drugs failed to help patients with mild COVID-19. The clinical trial's goal was to prove a study model's viability. It included investigating medication's potential arrhythmic side effects and how they can be safely and effectively monitored without the participants ever setting foot in a hospital or clinic. Although the drugs failed, the research had a silver lining. It showed the possibility of remote monitoring of the arrhythmic cardiac condition.
Related Reports:
Global Cardiac Medication Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027

Global Cardiac Monitoring Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

Global Cardiac Care Equipment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

Global Cardiac Resynchronization Therapy Systems Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026